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Abstract. Background: Pemetrexed (Alimta®) is a new-
generation multitargeted antifolate that inhibits several key
enzymes in the de novo pathways of pyrimidine and purine
biosynthesis, including thymidylate synthase (TS), dihydrofolate
reductase (DHFR) and glycinamide ribonucleotide
formyltransferase (GARFT). Alimta® has demonstrated
antitumor activity in a broad array of human malignancies, e.g.
breast, non-small cell lung cancer, malignant pleural
mesothelioma and pancreatic, colorectal, gastric, bladder, head
and neck cancer, and is currently in phase III clinical trials. It has
been reported that a dose of 600 mg/m2 of pemetrexed showed
toxicity to bone marrow and the gastrointestinal system. The aim
of this investigation was to evaluate raloxifene (RAL) in
combination with 5-fluorouracil (5-FU)/pemetrexed multitargeted
antifolate (MTA) to determine the most effective regimens and
cellular mechanism of action to mitigate pemetrexed cytotoxicity
in human bone marrow cells. Materials and Methods: In order to
determine the sequence-dependent interaction between MTA, 5-
FU and RAL on proliferation, cell viability was carried out using
the Quick Cell Proliferation Assay by exposing the HS-5 and
MCF-7 cells to (i) MTA, 5-FU and RAL alone, or (ii) RAL 24 h
prior to 5-FU followed 2 h later by MTA, or (iii) 5-FU 2 h prior to
MTA followed 24 h later by RAL. Results: The growth rate in
MCF-7 in early RAL was 69±8.65% and late RAL was
36±4.6% of the control, whereas in bone marrow early RAL was
78±8.65% and late RAL was 52±5.49% of the control. The late
RAL exhibits significant protection against MTA cytotoxicity in
bone marrow. The findings were further supported by cell flow
cytometry, apoptosis and Western blot analysis data. Conclusion:
This study suggests that sequence-dependent administration of
RAL (5FU/MTA/RAL), in combination with 5-FU/MTA,
protects against MTA toxicity in human bone marrow while
maintaining the maximum inhibitory effect of pemetrexed in
breast cancer.
The antimetabolites were among the first antineoplastic
agents discovered (1). Antimetabolites act by disrupting
cellular replication and division either by direct
incorporation into DNA, such as the purine and pyrimidine
analogues, or by interfering with the metabolic processes
necessary for DNA synthesis, as antifolates do. All cells,
both eukaryotic and prokaryotic, require folates for cell
growth. Folates transfer one-carbon units in the enzymatic
reactions of purine, thymidine and amino acid (histidine,
serine, methionine) biosynthesis (2). Folate-dependent
pathways are key targets in the development of anticancer
agents. Research into the development of antifolates as
anticancer agents has led to the development of the
multitargeted antifolate Alimta® (MTA) (3, 4).
Pemetrexed (Alimta®) is a new-generation multitargeted
antifolate (4-6). Alimta® is a novel pyrrolo[2,3-d]pyrimidine
based antifolate. Unlike the “classic” antimetabolic drug
methotrexate, which selectively targets a single enzyme,
pemetrexed exerts its action by disrupting several folate-
dependent metabolic processes essential for cell replication
through inhibiting multiple enzymes (7, 8). Both the reduced
folate carrier and membrane folate binding protein transport
systems transport pemetrexed into cells. Once in the cell,
MTA is converted to polyglutamate forms by the enzyme
folypolyglutamate synthesis. The polyglutamate forms are
retained in cells. MTA and its tri-and pentaglutamate
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derivatives (MTAPGs) have significant inhibitory activity
against thymidylate synthase (TS), glycinamide ribonucleotide
formyltransferase (GARFT), and to a lesser extent 
5-aminoimidazole-4-carboxamide ribonucleotide formyl-
transferase (AICARFT) and dihydrofolate reductase
(DHFR) (7, 8). Polyglutamation is a time- and concentration-
dependent process that occurs in tumor cells and, to a lesser
extent, in normal tissues. Polyglutamated metabolites have an
increased intracellular half-life resulting in prolonged drug
action in malignant cells. Pemetrexed has demonstrated
broad antitumor activity in several solid tumors, including
breast (9, 10), non-small cell lung cancer (11), malignant
pleural mesothelioma (12, 13), cervical cancer (14), colorectal
(15), pancreatic (16), gastric (17), bladder (18), head and
neck cancer (19).
Pemetrexed (Alimta®) is the first agent approved by the
US Food and Drug Administration in February 2004 for the
treatment of malignant pleural mesothelioma (MPM) in
combination with cisplatin in patients with unresectable
disease or for whom curative surgery is not an option. (4). It
has a moderate toxicity profile at a dose of 500 mg/m2 with
myelosuppression being the chief symptom of dose limiting
toxicity (20). A higher dose of 600 mg/m2 showed toxicity to
bone marrow and the gastrointestinal system (9, 21). Folic
acid co-administered with MTA decreased its toxicity while
maintaining antitumor activity (20). In August 2004,
pemetrexed was approved as a second-line, single agent
treatment of locally advanced or metastatic non-small cell
lung cancer (NSCLC) (4). In addition, pemetrexed has been
studied as a single agent and in combination regimens in
patients with breast, pancreatic, colorectal, gastric,
genitourinary, head and neck cancer and is currently in
Phase III clinical trials (20, 5). 
Inhibition of DHFR and TS has shown proven benefit
in breast cancer, and methotrexate and 5-FU are used in
combination regimens in the treatment of metastatic
breast cancer and as adjuvant therapy (5). With a
mechanism overlapping both methotrexate and 5-FU with
additional enzyme targets, pemetrexed may prove active
and offer additional benefit in the treatment of breast
cancer. Clinical development has also focused on
combining pemetrexed with other agents active against
breast cancer to identify highly functioning, well-tolerated
regimens for the adjuvant setting. Combining agents that
target different oncogenic pathways or multiple steps of
the same cascade is a promising strategy to explore in
developing the best regimen that will increase the options
available to a physician to treat breast cancer patients.
Preclinical evidence suggested that pemetrexed had
additive or synergistic activity when combined with many
other clinically important anticancer agents, including
gemcitabine (Gemzar®), fluorouracil, carboplatin
(Paraplatin®), oxaliplatin (Eloxatin®), paclitaxel, and
vinorelbine (Navelbine®) (5, 22). Studies have shown that
the sequence-dependent administration of raloxifene
(RAL) in combination with 5-FU/methotrexate has
maximum antineoplastic activity in breast cancer while at
the same time provides protection to the human bone
marrow (HS-5) cell line (23). Recent studies from this
laboratory also have shown that RAL attenuation of 5-
FU/MTA cytotoxicity to breast cancer cells was sequence-
dependent (24). In the present study a similar approach
was used for pemetrexed (MTA) in combination with
RAL and priming- and non-toxic 5-FU in protecting
human bone marrow cells from MTA cytotoxicity through
conservation of reduced folates and increasing the
additional therapeutic utility of multitargeted pemetrexed
in the treatment of breast cancer.
Materials and Methods 
Pemetrexed (Alimta®) was obtained from Eli Lilly and
Company Ltd., Indianapolis IN, USA. 5-FU, raloxifene
hydrochloride and Trypan blue dye were purchased from Sigma
Chemical Company, St. Louis, MO, USA. An early passage of
human bone marrow (HS-5) and breast cancer cell line (MCF-7)
were obtained from the American Type Culture Collection
(ATCC), Manassas, VA, USA. The BCA Protein assay kit,
PVDF membrane and Super Signal West Dura were purchased
from Pierce, Rockford IL, USA. Quick Cell Proliferation Assay
Kit was purchased from BioVision, CA, USA. Propidium iodide
(PI), Annexin V and Primary (Rb) antibody were obtained from
BD Biosciences, CA, USA.
Cell culture. Stock cultures of HS-5 bone marrow cells were grown
in 75 cm3 flasks and incubated in RPMI-1640 media (Cellgro,
Mediatech Inc., VA, USA). For each experiment, 1x106 cells were
plated in 60 mm tissue culture Petri-dishes. One group of cells
maintained without any drugs served as the control and the
remaining groups of cells were exposed to (i) MTA, 5-FU and
RAL alone, (ii) RAL 24 h prior to 5-FU followed 2 h later by MTA
(early RAL), or (iii) 5-FU 2 h prior to MTA followed 24 h later by
RAL (late RAL). Drug concentrations were 10 ÌM MTA, 1 ÌM 5-
FU and 10 ÌM RAL. Cells were exposed for 48 h.
Assessment of cell viability using the quick cell proliferation assay.
Cell viability studies were performed using the quick cell
proliferation assay following the manufacturer's protocol. Briefly,
the HS-5 and MCF-7 (1.5x104 cells) growing in 96-well plates in
RPMI-1640 media in the presence or absence of drugs added in
the same sequence as described above. The formazan dye produced
by viable cells was quantified by measuring the absorbance of the
dye solution at 440 nm using a microtiter plate reader.
Furthermore, Trypan blue dye exclusion assay was performed by
staining the cells with 0.2% Trypan blue dye and then counting
cells in a heamocytometer. 
Cell cycle analysis. Cell cycle perturbations induced by the inhibitor
were analyzed by propidium iodide (PI) DNA staining as described
elsewhere (23). The cells were grown in 6-well plates (1x105 cells
per well) in the presence or absence of the above-mentioned drugs.
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After 48 h of exposure cells were collected and evaluated after
propidium iodide staining and cell cycle profiles were obtained
using a BD FACScan Cell flow Cytometer (Becton Dickinson
Italia). Data were analyzed by ModFit LT software (Verity
Software House, Inc., Topsham, ME, USA).
Apoptosis assay. To quantify drug-induced apoptosis, annexin
V/propidium iodide staining was carried out followed by flow
cytometry. Briefly, after drug treatments, both floating and
attached cells were combined and subjected to annexin
V/propidium iodide staining using an annexin V-FITC apoptosis
detection kit according to the protocol provided by the
manufacturer. Untreated control cells were maintained in parallel
to the drug treatment group. Double staining was used to
distinguish between viable, early apoptotic and necrotic or late
apoptotic cells. The resulting fluorescence was measured using flow
cytometry using a FACScan flow cytometer (Becton Dickinson).
According to this method, the lower left quadrant shows the viable
cells, the upper left quadrant shows cell debris, the lower right
quadrant shows the early apoptotic cells and the upper right
quadrant shows the late apoptotic and necrotic cells.
Western blot analysis. Western blot was performed as described
elsewhere (23). The mouse anti-human retinoblastoma protein Rb
monoclonal antibody was used in conjunction with horseradish
peroxidase-conjugate. Antibody detection and densitometric
analysis were performed as described (23). 
Statistical analyses. Data were expressed as mean±standard error.
Statistical differences within and between treatment groups were
determined in HS-5 and MCF-7 cell lines by One-way ANOVA
followed by Newman-Keuls Multiple comparison test. P<0.05 was
considered statistically significant. Data were analyzed for both
control and treatment groups using Graphpad Prism 3 (Graphpad
Software, Inc, San Diego, CA, USA). 
Results
Effect of MTA, 5-FU and RAL on the growth of human bone
marrow and breast cancer cell lines. The growth rate in HS-5
for MTA, 5-FU and RAL alone was 39±5.78%, 65±7.59%,
and 92±10.98% that of the control, respectively. The growth
rate for early RAL was 78±7.95% and for late RAL
52±5.49% that of the control. A significant reduction in cell
growth compared to the control as well as RAL alone was
observed with MTA and 5-FU. Late RAL showed greater
cytotoxicity than early RAL and also showed significant
growth reduction when compared with the control (Figure
1). RAL alone had no significant effect when compared with
the control, whereas RAL with 5-FU and MTA combination
significantly decreased the growth rate. The growth rate in
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Figure 1. The sequence-dependent interaction between MTA, 5-FU and RAL on the proliferation of human bone marrow HS-5 cells. Cells were exposed
to (i) 10 ÌM MTA, 1 ÌM 5-FU and 10 ÌM RAL alone, (ii) RAL 24 h prior to 5-FU followed 2 h later by MTA, and (iii) 5-FU 2 h prior to MTA followed
24 h later by RAL. Total time of exposure was 48 h. Viability of cells was determined using the Quick Cell Proliferation assays. Results represent
mean±SEM of five independent experiments. Analysis of variance indicated a significant reduction compared with the control (*p<0.05, **p<0.01,
***p<0.001) and compared with RAL (+p<0.05, ++p<0.01, +++p<0.001).
MCF-7 with early RAL was 69±8.65%, and late RAL
36±4.6% that of the control, whereas in bone marrow the
early RAL combination yielded 78±7.95%, and the late
52±5.49%, compared to the control. The late RAL
combination exhibited a significant protective effect on the
MTA cytotoxity in bone marrow cells and same time
maintained antineoplastic activity in breast cancer cells. The
level of significance with late RAL was p<0.01 when MCF-
7 cells were compared with bone marrow cells (Figure 2). 
Effect of MTA, 5-FU and RAL on the cell cycle progression of
human bone marrow cell line: 
Cell flow cytometry analysis. Cell flow cytometry was used on
the treatment groups to determine the effect of RAL on the
progression of cells when exposed to S-phase agents. The
cell cycle profile (Figure 3A) is representative of four
independent experiments using the six treatment groups in
HS-5 cells. Figure 3B shows the percentage of cells in the
S-phase. Analysis revealed that the highest number of cells
progressing to the S-phase of the cell cycle was found in 5-
FU alone (52±5.21%) followed by MTA alone (38±3.5%),
early RAL (32±4.15%) then late RAL (29±2.5%). These
numbers were significantly greater when compared with
RAL alone the lowest number of cells entering S-phase was
observed in cells treated with RAL alone.
Apoptosis. Drug-induced apoptosis was measured using cell
flow cytometry. The apoptosis profile (Figure 4A) is
representative of four independent experiments using the
six treatment groups in HS-5 cells. The percentage of early
plus late apoptotic cells was highest with MTA alone
(48±4.5%) followed by 5-FU alone (14±2.1%) then early
RAL (10±1.5%) and late RAL (5±1%) as shown in Figure
4B. Significant reductions of apoptotic cell death were
observed in early and late RAL combination compared with
MTA and the late RAL combination showed no significant
apoptosis when compared with control.
Western blot analysis. The retinoblastoma protein (Rb), a
cell cycle regulator, which when phosphorylated allows the
progression of cells from the G1-to the S-phase, was used
as a marker to determine the effects of early RAL and late
RAL on cellular progression at the molecular level. The
Western blot shown in (Figure 5A) is representative of five
independent experiments using the six treatment groups.
The relative optical density (ROD) is shown in Figure 5B.
The highest density was observed in 5-FU and early RAL,
followed by late RAL and MTA, indicating higher
phosphorylation. The lowest density was found in RAL
alone, indicating fewer phosphorylated Rb proteins were
present. Results revealed that the highest number of cells
progressing to the S-phase of the cell cycle was found in 5-
FU and early RAL, followed by late RAL. These
differences were significant when compared to the control
as well as to the results with RAL alone. Similar results
were observed with the cell flow cytometry analysis.
Discussion
The pharmacological activity of pemetrexed is achieved
after its conversion to a polyglutamated form; the
pentaglutamated form is the most predominant (8). The
formation of polyglutamated metabolites is essential for
intracellular accumulation and retention of antimetabolites.
Pemetrexed is one of the best known substrates for
folypolyglutamate synthetase (FPGs) with an inhibition
constant Ki of 1.6 ÌM, pemetrexed is polyglutamated 90-195
times more efficiently than methotrexate (25). In addition,
the intracellular retention of the polyglutamated forms
increases the affinity of pemetrexed to its cellular targets by
several orders of magnitude. 
Earlier studies from this laboratory showed that the
effect RAL in combination with 5-FU/MTA on the growth
of MCF-7 breast cancer cells was sequence-dependent
(24). In the present study, the late RAL combination
showed significant protection of the human bone marrow
cells compared to the breast cancer cell line (Figure 2).
This study raises a new element in the potential for
dihydrofolate (DHF) polyglutamates to influence the
selective effects of a priming non-toxic 5-FU dose with
MTA. The selective cytotoxicity of MTA in breast cancer
cells may be due to the formation of pentaglutamated
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Figure 2. Effects of MTA, 5-FU and RAL on the growth of MCF-7 and HS-
5 cells. Cells were exposed to (i) 10 ÌM MTA, 1 ÌM 5-FU and 10 ÌM RAL
alone, (ii) RAL 24 h prior to 5-FU followed 2 h later by MTA, and (iii) 5-FU
2 h prior to MTA followed 24 h later by RAL. Total time of exposure was 48
h. Analysis of variance indicated a significant increase in growth rate of HS-
5 cells in late RAL compared with MCF-7 cells (**p<0.01).
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Figure 3. The sequence-dependent interaction between MTA, 5-FU and RAL on the cell cycle progression of human bone marrow HS-5 cells. Cells were
exposed to (i) 10 ÌM MTA, 1 ÌM 5-FU and 10 ÌM RAL alone, (ii) RAL 24 h prior to 5-FU followed 2 h later by MTA, and (iii) 5-FU 2 h prior to MTA
followed 24 h later by RAL. A: The cell cycle profile is representative of four independent experiments. B: Percentage of cells in S-phase.
pemetrexed and feedback inhibition of TS, GARFT, and
to a lesser extent of AICARFT and DHFR (7, 8). Whereas
in bone marrow, little or no DHF-polyglutamates form
when exposed to MTA, and therefore, feedback inhibition
on TS, GARFT and/or AICARFT would not be
significant. Hence, sequence-dependency effect on bone
marrow cells might best be related to 5-FU conserving
reduced-folates to protect against the direct effects of
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Figure 4. Effects of MTA, 5-FU and RAL on the apoptosis of human bone marrow HS-5 cells. Cells were exposed to (i) 10 ÌM MTA, 1 ÌM 5-FU and
10 ÌM RAL alone, (ii) RAL 24 h prior to 5-FU followed 2 h later by MTA, and (iii) 5-FU 2 h prior to MTA followed 24 h later by RAL. A: Apoptosis
analysis profile is representative of four independent experiments. B: Percent of early plus late apoptotic cells. Analysis of variance indicated a significant
increase compared with control (*p<0.05, **p<0.01, ***p<0.001) or significant decrease compared with MTA (+++p<0.001).
MTA. RAL alone did not exhibit significant toxicity,
however, RAL combined with 5-FU and MTA showed
significant toxicity. Late RAL was significantly more
cytotoxic in MCF-7 breast cancer cells than HS-5 bone
marrow cells. The selective cytotoxicity of late RAL may
be due to the conservation of reduced folates in bone
marrow by 5-FU as previously mentioned.
The results of cell flow cytometry and Western blot
showed significantly fewer cells entering the S-phase of the
cell cycle when cells were treated with RAL alone. Early
RAL in combination with 5-FU and MTA demonstrated a
greater number of cells entering the S-phase compared with
late RAL. Based on the sequence of RAL administration,
HS-5 cells were exposed to RAL for 48 h with the early
RAL regimen and 24 h with the late RAL regiman. Hence,
RAL may interfere with the transition between the G1- and
the S-phase and the release of an E2F transcription factor
thereby decreasing the activity of MTA, which arrests cells
in the S-phase. The growth rate of MCF-7 cells when
compared with bone marrow cells using the late RAL
combination showed significant protection in the bone
marrow cell line. The findings suggest that the
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Figure 5. Effect of MTA, 5-FU and RAL on the level of retinoblastoma protein (Rb) as phosphorylated protein marker in human bone marrow HS-5
cells. Cells were exposed to (i) 10 ÌM MTA, 1 ÌM 5-FU and 10 ÌM RAL alone, (ii) RAL 24 h prior to 5-FU followed 2 h later by MTA, and (iii) 5-FU
2 h prior to MTA followed 24 h later by RAL. A: The gel is representative of five independent experiments. B: Relative optical density. 
administration of RAL late in the sequence provides a
cytotoxic advantage for breast cancer cells since
hematopoietic cells (bone marrow) are protected by a non-
toxic dose of 5-FU in combination with MTA. 
MTA forms a stable complex with TS and dUMP that
inhibits binding of 5,10-methylene tetrahydrofolate to the
enzyme (7, 8). TS inhibition causes nucleotide pool
imbalances that result in S-phase cell cycle arrest and
apoptosis. It is known that apoptosis-signaling pathways and
cellular events controlling them have a profound effect both
on cancer progression and in response to chemotherapy
(26). Based on annexin V/propidium iodide staining it is
clear that the high apoptotic cell death observed in MTA
treated cells may have been due to MTA triggering or an
enhanced apoptotic response in these cells. Pemetrexed was
found to be a potent inducer of apoptosis in lymphocytic
leukemia cells (27). The early and late RAL combination
showed a significant reduction of apoptotic cell death
compared to pemetrexed. 
In conclusion, the observations from this study have
important implications regarding therapeutic dosing regime,
which include MTA in combination with a priming non-
toxic dose of 5-FU and RAL in the treatment of breast
cancer while protecting the bone marrow. This may increase
the therapeutic utility of pemetrexed in breast cancer: it has
a mechanism overlapping that of both methotrexate and 5-
FU along with additional enzyme targets offering an
additional benefit in the treatment of breast cancer while
protecting the human bone marrow. 
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